Skip to content

Efficacy and Neural Mechanisms of Eye-Tracking Virtual Reality Cognitive Assessment and Training Combined with Auricular Vagus Nerve Stimulation for Mild Cognitive Impairment After Stroke

Efficacy and Neural Mechanisms of Eye-Tracking Virtual Reality Cognitive Assessment and Training Combined with Auricular Vagus Nerve Stimulation for Mild Cognitive Impairment After Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124324
Enrollment
Unknown
Registered
2026-05-11
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Stroke Mild Cognitive Impairment

Interventions

Combined group:taVNS 20 min/session + eye movement VR training 30 min/session
VR group:Sham stimulation (left auricle, no current delivery), eye movement VR training 30 min/session
The tavns group:Active stimulation (left auricle), traditional cognitive training for 30 minutes per session.
Control group:Sham stimulation (left auricle, no current), conventional cognitive training 30 min/session

Sponsors

Guangdong Sanjiu Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clinically confirmed ischemic stroke (according to the criteria of "Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases", confirmed by MRI/CT) 2. Stable neurological function (NIHSS= 3 months 4. Age 30-70 years old, audio-visual function can be combined with VR

Exclusion criteria

Exclusion criteria: 1.Severe aphasia (Western Aphasia Battery, WAB-AQ 17). 2.Implanted electronic devices (e.g., pacemaker), ear infection or metallic implants (contraindications for taVNS). 3.History of epilepsy, severe motion sickness or vestibular dysfunction (contraindications for VR). 4.Other neurological diseases (e.g., Parkinson’s disease, Alzheimer’s disease, psychiatric disorders).

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment;

Secondary

MeasureTime frame
Blood indicators;Neuroimaging indicators;Autonomic nerve function indicators;Autonomic nerve function indicators;Safety indicators;

Countries

China

Contacts

Public ContactZhanhao Liu

Guangdong Sanjiu Brain Hospital

524066972@qq.com+86 159 1866 9852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026